A Biotech Startup Betting on a New Kind of Genetic Medicine

Biotech startup Moonwalk Biosciences has been operating quietly since 2022. It recently raised $57 million in venture capital. It’s one of a handful of companies focused on epigenetic medicine, a subset of genetic medicine that looks to treat disease by changing which genes are turned on and off. WSJ Pro VC reporter Brian Gormley joins host Alex Ossola to talk about the company, and the expanding field of epigenetic medicine.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Biotech startup Moonwalk Biosciences has been operating quietly since 2022. It recently raised $57 million in venture capital. It’s one of a handful of companies focused on epigenetic medicine, a subset of genetic medicine that looks to treat disease by changing which genes are turned on and off. WSJ Pro VC reporter Brian Gormley joins host Alex Ossola to talk about the company, and the expanding field of epigenetic medicine.

Learn more about your ad choices. Visit megaphone.fm/adchoices